title: Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.
abstract: We studied the efficacy of sitagliptin in type 2 diabetic patients of our outpatient clinics.  Since December in 2009, 164 patients have been treated by sitagliptin for their management of diabetes.  HbA1c decreased by 0.8% in all patients without any change in mean body weight after 3 months.  However, actually HbA1c did not decrease in 30 patients, and more than half of patients showed weight gain to some extent.  Patients were classified according to the reduction of HbA1c and analyzed based on this category.  Baseline characters such as age, gender, duration of diabetes, BMI, concomitantly used oral hypoglycemic agents and the score for life-style assessment were not related to glucose-lowering effect of sitagliptin.  Ninety eight patients whose HbA1c had decreased after 3 months were further followed-up for another 3 months.  Among them 45 patients showed some relapsing of HbA1c after 6 months, and they were compared with 53 patients without relapsing.  More cases had been switched from α-glucosidase inhibitor (α-GI) and the score for life-style assessment was lower in relapsing patients compared to those in patients without relapsing.  In conclusion, clinicians should keep the fact in mind that the individual variation of glucose-lowering effects and the possibility of relapsing exist during sitagliptin treatment, and that concern about life-style is still a quite important issue to prevent weight gain and the relapsing of blood glucose control.
authors.affiliation: Division of Endocrinology and Metabolism, Kurume University School of Medicine, Kurume 830-0011, Japan. tajiriy@med.kurume-u.ac.jp
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tajiri
authors.forename: Munehisa
authors.initials: M
authors.lastname: Tsuruta
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ohki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kato
authors.forename: Yuko
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Kayo
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shusuke
authors.initials: S
authors.lastname: Kono
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tojikubo
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007564:Japan; D008019:Life Style; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate